Prostaatspecifiek membraanantigeen radioligandtherapie met alfastralers, een review

Bastiaan M. Privé; Willemijn A.M. van Gemert; James Nagarajah; Niven Mehra; Winald R. Gerritsen; Inge M. van Oort; Martin Gotthardt; Sandra Heskamp; Marcel J.R. Janssen

doi:10.1007/s13629-020-00301-y

Prostaatspecifiek membraanantigeen radioligandtherapie met alfastralers, een review

Translated title of the contribution: Prostate-specific membrane antigen radioligand therapy with alpha emitters, a review

Bastiaan M. Privé^*, Willemijn A.M. van Gemert, James Nagarajah, Niven Mehra, Winald R. Gerritsen, Inge M. van Oort, Martin Gotthardt, Sandra Heskamp, Marcel J.R. Janssen

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

1 Citation (Scopus)

Abstract

Prostate-specific membrane antigen (PSMA) radioligand therapy is a novel treatment for castration-resistant prostate cancer (mCRPC). Currently, most data on PSMA radioligand therapy refer to ¹⁷⁷Lu-PSMA, a beta emitter. However, PSMA ligands can also be labelled to alpha emitting radionuclides, such as ²²⁵Ac. Compared to beta emitters, alpha decay induces more harmful DNA damage. Thus, alpha emitter labelled PSMA ligands may have a better therapeutic effect compared to their beta emitting counterparts. Moreover, alpha decay has a much shorter linear energy transfer which could be beneficial in patients with micrometastases or diffuse bone-marrow infiltration. However, alfa-PSMA radioligand therapy is still experimental as there is only retrospective data available and prospective studies are awaited. Hence, the results require to be interpreted with caution. Also, production of ²²⁵Ac and other alpha emitting isotopes needs to be increased significantly before clinical application. In this review, we summarize and discuss the current developments on alfa-PSMA radioligand therapy.

Translated title of the contribution	Prostate-specific membrane antigen radioligand therapy with alpha emitters, a review
Original language	Dutch
Pages (from-to)	147-154
Number of pages	8
Journal	Tijdschrift voor Urologie
Volume	10
Issue number	6-7
DOIs	https://doi.org/10.1007/s13629-020-00301-y
Publication status	Published - 26 Aug 2020
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2020, The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s13629-020-00301-y

Cite this

@article{b6d6e3bfc4a04b0eb2520e4b87c6dc00,

title = "Prostaatspecifiek membraanantigeen radioligandtherapie met alfastralers, een review",

abstract = "Prostate-specific membrane antigen (PSMA) radioligand therapy is a novel treatment for castration-resistant prostate cancer (mCRPC). Currently, most data on PSMA radioligand therapy refer to 177Lu-PSMA, a beta emitter. However, PSMA ligands can also be labelled to alpha emitting radionuclides, such as 225Ac. Compared to beta emitters, alpha decay induces more harmful DNA damage. Thus, alpha emitter labelled PSMA ligands may have a better therapeutic effect compared to their beta emitting counterparts. Moreover, alpha decay has a much shorter linear energy transfer which could be beneficial in patients with micrometastases or diffuse bone-marrow infiltration. However, alfa-PSMA radioligand therapy is still experimental as there is only retrospective data available and prospective studies are awaited. Hence, the results require to be interpreted with caution. Also, production of 225Ac and other alpha emitting isotopes needs to be increased significantly before clinical application. In this review, we summarize and discuss the current developments on alfa-PSMA radioligand therapy.",

author = "Priv{\'e}, {Bastiaan M.} and {van Gemert}, {Willemijn A.M.} and James Nagarajah and Niven Mehra and Gerritsen, {Winald R.} and {van Oort}, {Inge M.} and Martin Gotthardt and Sandra Heskamp and Janssen, {Marcel J.R.}",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = aug,

day = "26",

doi = "10.1007/s13629-020-00301-y",

language = "Dutch",

volume = "10",

pages = "147--154",

journal = "Tijdschrift voor Urologie",

issn = "2211-3037",

publisher = "Springer Science+Business Media",

number = "6-7",

}

TY - JOUR

T1 - Prostaatspecifiek membraanantigeen radioligandtherapie met alfastralers, een review

AU - Privé, Bastiaan M.

AU - van Gemert, Willemijn A.M.

AU - Nagarajah, James

AU - Mehra, Niven

AU - Gerritsen, Winald R.

AU - van Oort, Inge M.

AU - Gotthardt, Martin

AU - Heskamp, Sandra

AU - Janssen, Marcel J.R.

PY - 2020/8/26

Y1 - 2020/8/26

N2 - Prostate-specific membrane antigen (PSMA) radioligand therapy is a novel treatment for castration-resistant prostate cancer (mCRPC). Currently, most data on PSMA radioligand therapy refer to 177Lu-PSMA, a beta emitter. However, PSMA ligands can also be labelled to alpha emitting radionuclides, such as 225Ac. Compared to beta emitters, alpha decay induces more harmful DNA damage. Thus, alpha emitter labelled PSMA ligands may have a better therapeutic effect compared to their beta emitting counterparts. Moreover, alpha decay has a much shorter linear energy transfer which could be beneficial in patients with micrometastases or diffuse bone-marrow infiltration. However, alfa-PSMA radioligand therapy is still experimental as there is only retrospective data available and prospective studies are awaited. Hence, the results require to be interpreted with caution. Also, production of 225Ac and other alpha emitting isotopes needs to be increased significantly before clinical application. In this review, we summarize and discuss the current developments on alfa-PSMA radioligand therapy.

AB - Prostate-specific membrane antigen (PSMA) radioligand therapy is a novel treatment for castration-resistant prostate cancer (mCRPC). Currently, most data on PSMA radioligand therapy refer to 177Lu-PSMA, a beta emitter. However, PSMA ligands can also be labelled to alpha emitting radionuclides, such as 225Ac. Compared to beta emitters, alpha decay induces more harmful DNA damage. Thus, alpha emitter labelled PSMA ligands may have a better therapeutic effect compared to their beta emitting counterparts. Moreover, alpha decay has a much shorter linear energy transfer which could be beneficial in patients with micrometastases or diffuse bone-marrow infiltration. However, alfa-PSMA radioligand therapy is still experimental as there is only retrospective data available and prospective studies are awaited. Hence, the results require to be interpreted with caution. Also, production of 225Ac and other alpha emitting isotopes needs to be increased significantly before clinical application. In this review, we summarize and discuss the current developments on alfa-PSMA radioligand therapy.

UR - http://www.scopus.com/inward/record.url?scp=85089913763&partnerID=8YFLogxK

U2 - 10.1007/s13629-020-00301-y

DO - 10.1007/s13629-020-00301-y

M3 - Review article

AN - SCOPUS:85089913763

SN - 2211-3037

VL - 10

SP - 147

EP - 154

JO - Tijdschrift voor Urologie

JF - Tijdschrift voor Urologie

IS - 6-7

ER -

Prostaatspecifiek membraanantigeen radioligandtherapie met alfastralers, een review

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this